JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL

Preventing or overcoming resistance to the Bcl‐2 inhibitor venetoclax is an emerging unmet clinical need in patients with chronic lymphocytic leukaemia (CLL). The upregulation of anti‐apoptotic Bcl‐2 members through signalling pathways within the tumor microenvironment appears as a major factor lead...

Descripción completa

Detalles Bibliográficos
Autores principales: Haselager, Marco V., Thijssen, Rachel, Bax, Danique, Both, Demi, De Boer, Francien, Mackay, Simon, Dubois, Julie, Mellink, Clemens, Kater, Arnon P., Eldering, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257415/
https://www.ncbi.nlm.nih.gov/pubmed/36550750
http://dx.doi.org/10.1002/1878-0261.13364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257415/
https://www.ncbi.nlm.nih.gov/pubmed/36550750
http://dx.doi.org/10.1002/1878-0261.13364

Ejemplares similares